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One-third of patients with medulloblastoma die due to recurrence after various treatments including radiother-
apy. Although it has been postulated that cancer stem-like cells are radio-resistant and play an important role
in tumor recurrence, the “stemness” of medulloblastoma cells surviving irradiation has not yet been eluci-
dated. Using a medulloblastoma cell line ONS-76, cells that survived gamma irradiation were investigated on
their “stemness” in vitro. From 10 500 cells, 20 radio-resistant clones were selected after gamma ray irradi-
ation (5 Gy × two fractions) using the replica micro-well technique. These 20 resistant clones were screened
for CD133 positivity by flow cytometry followed by side population assay, tumor sphere formation assay and
clonogenic survival assay. Results revealed CD133 fractions were significantly elevated in three clones, which
also exhibited significantly increased levels of tumor sphere formation ability and side population fraction.
Clonogenic survival assay demonstrated that their radio-resistance was significantly higher than the parental
ONS-76. This may support the hypothesis that a small number of cancer stem-like cells (CSCs) are the main
culprits in local recurrence after radiotherapy, and disruption of the resistance mechanism of these CSCs is a
critical future issue in improving the outcome of patients with medulloblastoma.
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INTRODUCTION
Medulloblastoma is the most common pediatric central
nervous system (CNS) tumor with an incidence of 0.5 per
100 000 children in Japan, and 0.65 per 100 000 in Europe
[1]. Approximately 75% of medulloblastomas develop in
the cerebellar vermis and it is most commonly seen at ages
6–7 years of age [1]. Although the current standard care for
medulloblastoma consists of maximum surgical removal
followed by conventional radiotherapy and concomitant
chemotherapy [2–3], approximately one-third of patients die
due to tumor recurrence [4]. Recurrence occurs not only
because of the invasive and metastatic nature of the tumor
[2], but also due to the restrictions on radiation doses to the
CNS in children [5–7]. Another biological factor leading to
treatment failure in one-third of patients may be tumor het-
erogeneity; a small mingled cell population survives
chemo-radiotherapy and regenerates the tumor mass al-
though most of the tumor cells are relatively sensitive to
chemo-radiotherapy.
Recently, it has been suggested that the cancer stem-like
cells (CSCs) are radio-resistant and may be involved in ma-
lignant brain tumor recurrence after radiotherapy [8–11].
Among these, CSCs in medulloblastoma have been reported
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to be enriched in CD133-positive cells and to have tumor
sphere formation ability [12–13]. In addition, it was
reported that the side population fraction is closely related
to the stemness of medulloblastoma cells through the Notch
pathway [14]. Thus, to elucidate the mechanism of recur-
rence after chemo-radiotherapy in patients with medullo-
blastoma, it is essential to confirm that the medulloblastoma
cells which survive irradiation contain radio-resistant CSCs.
Based on this background, we recreated the process of
tumor recurrence after X-ray irradiation in vitro to prove the
hypothesis that a small population of survivors is not only
radio-resistant but also has the characteristics of CSCs.
MATERIALS AND METHODS
Cell line and culture condition
A human medulloblastoma cell line, ONS-76, was obtained
from the RIKEN Cell Bank (Tsukuba, Ibaraki, Japan).
ONS-76 was established from a primary culture of tumor
tissue taken from a 2-year-old Japanese girl in 1987 [15]. It
has been reported that ONS-76 possesses the neuronal cell
markers neuron-specific enolase (NSE) and neurofilament
protein (NFP) in the cytoplasm. Also, the ONS-76 line
expresses class I and II major histocompatibility complex
(MHC) following administration of interferon-gamma
(IFN-γ). These phenomena suggest that ONS-76 can differ-
entiate into both neural cells and glial cells; thus, ONS-76
may be kept in an undifferentiated or early differentiation
state and may have neural stem cell-like properties [15].
Also, we have previously reported that ONS-76 cells form
clear colonies with high plating efficiency [16], and a
recent report defined that ONS-76 has wild-type p53 [17].
The cells were cultured in minimal essential medium
(MEM) (Sigma-Aldrich Inc., Tokyo, Japan) containing
10% fetal bovine serum (FBS) (Nichirei Biosciences Inc.,
Tokyo, Japan), 100 mg/ml streptomycin and 100 U/ml
penicillin (Sigma-Aldrich). The cells were incubated in a
humidified atmosphere at 37°C with 5% CO2 in the air. For
subcultures, cells were rinsed with Ca2+ and Mg2+-free
phosphate buffered saline (PBS) (Sigma-Aldrich), and were
dispersed with 0.25% trypsin containing 0.5 mM of ethyle-
nediaminetetraacetate (EDTA) (Sigma-Aldrich).
Irradiation and dosimetry
ONS-76 cells in a logarithmic growing phase were irra-
diated with 137cesium γ-rays at a dose rate of approximately
0.9 Gy/min using Gammacell (Atomic Energy, Ottawa,
ON, Canada). Irradiation was performed at room tempera-
ture. Dosimetry at the same position was performed using a
small chip photoluminescence glass dosimeter (PLD)
system (Dose Ace; Asahi Techno Glass Co., Japan).
Isolation of surviving cells after irradiation
To isolate surviving clones after irradiation, the modified
replica micro-well method was performed (Supplemental
Fig. 1) [18]. First, ONS-76 cells in flasks were irradiated
with 5 Gy of γ-rays. Then, the cells were trypsinized and
suspended in MEM, and 350 cells were counted and
seeded into thirty 10-cm dishes (Falcon, Becton Dickinson,
Franklin Lakes, NJ, USA). After two weeks of incubation,
the 96 largest colonies were selected and sampled by
custom-made cloning cylinders, and transferred to three
identical 96-well plates (Falcon, Becton Dickinson). After
incubation for 24 h, one of the three plates was irradiated
with 5 Gy of γ-rays again and the three plates were incu-
bated for another 5 days. Finally, the cells in the irradiated
plate and one of two unirradiated plates were fixed and
stained with 0.25% methylene blue (Wako Pure Chemical
Industries Ltd, Osaka, Japan) in 90% ethanol solution.
Comparing the two stained plates macroscopically, the
deep-colored candidates were selected and harvested from
the corresponding wells of the remaining plate.
Immunocytochemistry by flow cytometry
The cells were detached by 0.25% trypsin-EDTA, and
washed in PBS containing 2% FBS. Then, 2 × 106 cells
were suspended in 80 µl of PBS with 2% FBS, and 20 µl of
FcR blocking reagent (Miltenyi Biotec Inc., Tokyo, Japan)
and 10 µl of anti-human CD133/1 mouse IgG1 antibody
conjugated to phycoerythrin (PE) was added (Miltenyi
Biotec). PE-labeled mouse IgG1 (BD Biosciences, Franklin
Lakes, NJ, USA) was used as an isotype control. The cell
suspension supplemented with these antibodies was incu-
bated at 4°C in the dark. After 30 min of incubation, the
cells were washed twice in PBS containing 2% FBS, and
then propidium iodide (PI) (Sigma-Aldrich) was added at a
final concentration of 1 µg/ml to eliminate dead cells. The
treated cells were filtered through a 35-µm cell strainer
before flow cytometry (BD FACSCalibur; BD Biosciences).
Tumor sphere limiting dilution assay
For limiting dilution assay, ONS-76 cells were dissociated
with 0.25% trypsin-EDTA and suspended in PBS contain-
ing 2% FBS. Then, PI was added at a final concentration of
1 µg/ml, and PI-negative cells were sorted by MoFlo
(Beckman Coulter Inc., Brea, CA, USA). The selected cells
were counted and plated at numbers of 2, 5, 8, 10 and 20
cells per well of the ultra low attachment surface 96-well
(Corning Inc., Lowell, MA, USA). The numbers of the
cells were plated in 12 wells each of which contained 200 µl
of serum-free medium (SFM) composed of Dulbecco’s
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/
F12) medium (GIBCO, Life Technologies, Carlsbad, CA,
USA), 20 ng/ml epidermal growth factor (EGF) (Sigma-
Aldrich), 20 ng/ml basic fibroblast growth factor (bFGF)
L. Sun et al.62
(Sigma-Aldrich) and 20 µl/ml B27 supplement (GIBCO,
Life Technologies). During incubation, the cells in the
wells were fed with 0.025 ml of SFM on Days 2, 4 and
6. Finally, wells that did not contain spheres were selected
macroscopically and their numbers counted on Day 7. The
percentage of wells without tumor spheres was calculated
and plotted against the number of cells plated per well.
From the regression curves, x-intercept values were extra-
polated to represent the number of cells required to form at
least one tumor sphere in each clone.
Side population analysis
The cells were trypsinized, washed and resuspended at 106
cells/ml in Hank’s balanced salt solution (HBSS) (Lonza
Walkersville Inc., Walkersville, MD, USA) containing 3%
FBS and 10 mM HEPES (GIBCO, Life Technologies).
Then, Hoechst 33342 (Dojindo, Kumamoto, Japan) was
added at a final concentration of 8 µg/ml with or without
15 µM reserpine (Sigma-Aldrich). Reserpine was used here
because it is an adenosine-triphosphate (ATP)-binding cas-
sette (ABC) transporters antagonist. It has been used to
evaluate or confirm the presence of side-populations as it is
able to selectively extinguish side-populations by its specif-
ic function [19]. After incubation at 37°C/5% CO2 for 90
min with gentle agitation every 30 min, cells were washed
twice with ice-cold HBSS containing 3% FBS and 10 mM
HEPES, followed by and addition of PI to a final concen-
tration of 1 µg/ml. Finally, the cells were filtered through a
35-µm cell strainer (Falcon, Becton Dickinson) to obtain
single-cell suspensions, and placed on ice until analysis.
Aliquots of 5 × 105 or more cells were analyzed by
MoFlo (Beckman Coulter). The Hoechst 33342 dye was
excited by a 350-nm laser, and subjected to dual-
wavelength analysis using a 457/50 (Hoechst blue) band-
pass filter and 670/30 band-pass filter (Hoechst red). The
PI was excited with a 488-nm laser and measured through
the 670/30 band-pass filter for discrimination of dead cells.
Clonogenic survival assay
The cells in flasks were exposed to γ-rays with dose values
of 1, 2, 4, 6, 8 and 10 Gy. After irradiation, the cells were
trypsinized and counted, and the predetermined number of
cells was plated onto five 60-mm dishes (Falcon, Becton
Dickinson) at each dose point. After 14 days incubation,
the colonies were fixed and stained with methylene blue so-
lution 0.25% methylene blue (Wako Pure Chemical
Industries) in 90% ethanol solution. The number of surviv-
ing colonies that include 50 cells or more was counted and
averaged [20]. The survival curves were fitted to the linear-
quadratic (LQ) model using DeltaGraph v.5.4 software
(RedRock Software, Inc., Salt Lake City, UT, USA) as pre-
viously described [16].
Growth pattern and CD133-positive cell fraction
analysis
The growth rates and CD133 positivity were analyzed sim-
ultaneously. Before the experiment, 1 × 106 cells were
plated in T75 flasks (NUNC) and pre-incubated for 3 days.
Then the cells were trypsinized and plated at a density of
1 × 106 cells/flask in T75 flasks. The numbers were
counted using a Coulter Counter (Beckman Coulter) every
24 h. The ratios of CD133-positive cells were analyzed
simultaneously by the above-mentioned method.
Statistical analysis
Experiments were performed three times each. The mean
and standard deviations (SD) were calculated at each data
point. Student’s t test was used to analyze the significance
of differences between groups. A probability (P) value of
less than 0.05 was regarded as statistically significant. In
Fig. 1. Results of CD133 positivity analyses on the selected clones and the parental cells by flow cytometry. ONS-76
(A), ONS-F8 (B), ONS-B11 (C) and ONS-F11 (D) are results with CD133-PE antibody. ONS-76 (E), ONS-F8 (F),
ONS-B11 (G) and ONS-F11 (H) are results with an isotype control antibody.
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addition, linear regression analysis and confidence interval
estimation were performed on the results of colony survival
assay in which the 10% survival values (D10) were
obtained and surviving fraction at 2 Gy exposure (SF2)
were calculated.
RESULTS
Isolation of surviving cells after irradiation
After γ-ray irradiation with 5 Gy, approximately 10 500
ONS-76 cells in total number were seeded in 30 dishes.
Consequently, 1440 colonies (13.7%) were formed after 2
weeks of incubation. From these colonies, 96 large colonies
were selected by eye. Then, after another 5 Gy of γ-ray ir-
radiation, 20 clones with high proliferative potency were
selected and used in the further analyses (Supplemental
Fig. 2 and Supplemental Fig. 4).
Screening of CD133 positivity
The results of CD133 positivity screening in the 20 clones
are shown in Table 1. Parental ONS-76 contained 3.77% ±
0.09% CD133-positive cells (Fig. 1 and Table 1). The iso-
lated clones showed a wide variation of CD133 positivities
ranging from 0.06% to 43.91% (Table 1). Of these 20
clones, 12 clones showed a decreased CD133 positivity
while 8 clones showed an increased CD133 positivity as
compared with the parental ONS-76 cell line. Among 8
clones with increased CD133 level, 3 clones, namely
ONS-F8, ONS-B11 and ONS-F11, showed significantly
higher CD133-positive ratios of 25.30% ± 0.41%, 43.91% ±
2.08% and 14.19% ± 0.75%, respectively (Fig. 1 and
Supplemental Fig. 3A). Thus, further analyses were focused
on these three clones and the parental ONS-76 cell line.
Tumor sphere formation ability
The results of tumor sphere formation assay of ONS-76,
ONS-F8, ONS-B11 and ONS-F11 demonstrate that the
calculated numbers of cells required to form at least one
tumor sphere/well were 23.2 ± 0.9 in ONS-76, 10.8 ± 0.6
in ONS-F8, 10.3 ± 0.5 in ONS-B11 and 13.2 ± 2.3 in
ONS-F11 (Fig. 2). Statistical analyses demonstrated that
three isolated clones with high CD133 positivity have
significantly higher tumor sphere formation ability as
compared with the parental ONS-76 (Supplemental
Fig. 3B).
Fig. 2. Results of the tumor sphere formation assay. Photographs
show tumor spheres from ONS-76 (A), ONS-F8 (B), ONS-B11 (C)
and ONS-F11 (D). The black bar in the panel D indicates 300 µm
in length. The tumor sphere formation abilities in ONS-76 (closed
circles), ONS-F8 (open circles), ONS-B11 (closed squares) and
ONS-F11 (open squares) were determined by the limiting dilution
assay.
Table 1. CD133 positive ratios in 20 isolated clones
Clones
CD133-positive
ratio (%)
Clones
CD133-positive
ratio (%)
ONS-76 3.77
ONS-B11 43.91 ONS-H1 0.98
ONS-F8 25.30 ONS-B5 0.98
ONS-F11 14.19 ONS-D2 0.43
ONS-C7 7.21 ONS-H7 0.35
ONS-G8 6.34 ONS-C8 0.3
ONS-E10 6.29 ONS-B10 0.3
ONS-A6 5.85 ONS-E4 0.24
ONS-C1 5.35 ONS-B3 0.23
ONS-C10 3.46 ONS-H8 0.2
ONS-A10 1.06 ONS-C5 0.06
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Percentage of side population cells
As shown in Fig. 3A–D, the percentages of the side
population in ONS-76, ONS-F8, ONS-B11 and ONS-F11
were 0.14% ± 0.02%, 0.26% ± 0.02%, 0.33% ± 0.05% and
0.24% ± 0.02%, respectively. In each case, the side popula-
tion was decreased significantly after treatment with reser-
pine (15 mg/ml) (Fig. 3E–H). Statistical analyses demonstrated
that these three isolated clones had significantly higher side
population cell fractions as compared with the parental
ONS-76 (Supplemental Fig. 3C).
Clonogenic survival assay
To validate the radio-resistance of the three clones with
high CD133 positivity, standard clonogenic survival assay
was performed, and the results are shown in Fig. 4. The
mean data points for each radiation treatment were curve-
fitted by the LQ model. The error bars on the survival
curves indicate the SD calculated from three independent
experiments. The 10% survival values (D10) were 5.68 ±
0.13 Gy in ONS-76, 6.53 ± 0.15 Gy in ONS-F8, 6.64 ±
0.08 Gy in ONS-B11 and 6.26 ± 0.07 Gy in ONS-F11, and
the survival fractions at 2 Gy (SF2) were 0.64% ± 0.03% in
ONS-76, 0.82% ± 0.06% in ONS-F8, 0.90% ± 0.05% in
ONS-B11 and 0.81% ± 0.07% in ONS-F11 (Table 2).
Considering a 95% confidence interval (CI), these three
isolated clones had significantly higher SF2 values as com-
pared with the parental ONS-76 (Table 2).
Growth pattern and CD133-positive cell fraction
As shown in Fig. 5A, the numbers of cells of the three
clones became greater than that of ONS-76 after 96 h of in-
cubation although their growth patterns were similar. Also,
it was shown that compared with CD133-negative cells, the
percentage of CD133-positive cells in the three clones
Fig. 3. Results of the side-population analysis. ONS-76 (A), ONS-F8 (B), ONS-B11 (C) and ONS-F11 (D) are results
of flow cytometry with Hoechst 33342. ONS-76 (E), ONS-F8 (F), ONS-B11 (G) and ONS-F11 (H) are results after
treatment with reserpine. Note that the side-population disappeared in E, F, G and H.
Fig. 4. Results of the clonogenic survival assay.(A) Survival curves of ONS-76 (closed circles) and ONS-F8 (open circles). (B)
Survival curves of ONS-76 (closed circles) and ONS-B11 (closed circles). (C) Survival curves of ONS-76 (closed circles) and
ONS-F11 (open triangles). The survival parameters were calculated by curve fitting with the LQ model. Error bars indicate
standard deviation.
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Fig. 5. Chronological changes of cell counts and CD133-positive fractions of the selected clones and the parental cells. (A) Cell
counts (line graphs) and CD133-positive fractions (bar graphs) of ONS-76, ONS-F8, ONS-B11 and ONS-F11 were plotted against
time. (B) Cell counts of CD133-positive cells (solid lines) and CD133-negative cells (dotted lines) of ONS-76, ONS-F8,
ONS-B11 and ONS-F11 were plotted against time. Cell counts were normalized to 1 at 0 h. (C) Increase rates (%) of
CD133-positive and CD133-negative cells of ONS-76, ONS-F8, ONS-B11 and ONS-F11at the time-points indicated. Error bars
indicate standard deviation.
Table 2. Calculated parameters of survival curves of ONS-76, ONS-F8, ONS-B11 and ONS-F11
α(Gy−1) ± 95% CI β(Gy−2) ± 95% CI R2 SF2 ± 95%CI D10 (Gy) ± 95% CI
ONS-76 0.13 ± 0.03 0.05 ± 0.003 0.99 0.64 ± 0.03 5.68 ± 0.13
ONS-F8 −0.01 ± 0.05 0.06 ± 0.005 0.99 0.82 ± 0.06 6.53 ± 0.14
ONS-B11 −0.07 ± 0.04 0.06 ± 0.005 0.99 0.90 ± 0.05 6.64 ± 0.08
ONS-F11 −0.016 ± 0.02 0.06 ± 0.004 0.99 0.81 ± 0.02 6.26 ± 0.07
Values of α and β with ±95% confidence interval (CI), and the coefficient of determination (R2) were calculated by curve fitting
with linear-quadratic (LQ) model. Values of SF2 indicate surviving fractions at dose of 2 Gy. D10 indicates dose corresponding to
10% surviving fraction. Values of 95% CI were calculated from three independent experiments.
L. Sun et al.66
decreased from 0 to 48 h, and they increased rapidly from
48 to 72 h (Fig. 5B). The calculated maximum growth rates
of CD133-positive cells were 310% ± 50% in ONS-76,
768% ± 96% in ONS-F8, 1338% ± 174% in ONS-B11 and
2053% ± 323% in ONS-F11 (Fig. 5C), which were signifi-
cantly greater than the growth rates of 300% or less in
CD133-negative cells in every cell line.
DISCUSSION
It has been postulated that a very small number of CSCs in
tumor tissue survive radiotherapy and lead to tumor regen-
eration in various malignant tumors [21–22]. However, it
has not been clarified whether radio-resistant subpopula-
tions possess stemness in medulloblastoma cells. In this
study, we aimed to confirm that medulloblastoma cells that
survived γ-ray irradiation contain cells with stem cell-like
characteristics in vitro. Thus, we recreated the process of
tumor recurrence in vitro using γ-ray irradiation followed
by resistant cell selection and characterizing their stemness.
Several attempts have been made to establish radio-
resistant cells after exposure to single or fractionated irradia-
tions, and their radio-resistant nature have been analyzed
[23–24]. Wei et al. selected radio-resistant cells from human
fibrosarcoma HT1080 through exposure to 2 Gy per day,
5 days per week for 7 months. Their radio-resistant cells had
different G-banded karyotypes compared with parental cells
[23]. Also, Tang et al. established two radio-resistant sublines
of human hepatocellular carcinoma HepG2 cells by exposure
to 2 Gy of γ-rays for 10 days or 10 Gy for 2 days. They
found radio-resistant cells had a greater extent of potentially
lethal damage repair (PLDR) and over-expression of Raf-1
[24]. More recently, Kuwahara et al. established radio-
resistant cells from a human hepatocellular carcinoma cell
line, HepG2, in which the cells were exposed once to 2 Gy
of α-particles with boron neutron capture, followed by
0.5 Gy of X-rays at every 12-h interval for more than 6 years
associated with 2 Gy of X-rays per day for 30 consecutive
days [25–26]. These reported methods were most likely
intended to induce mutations by irradiation over a certain
period of time to produce stably radio-resistant cells. In con-
trast, our purpose here was to recreate tumor recurrence after
radiotherapy and to evaluate stemness in surviving cells.
Thus, we used a modified replica micro-well method to
select clones after 5 Gy of γ-irradiation twice, based on our
previous data that 5 Gy corresponded to approximately 20%
survival in ONS-76 (Supplemental Fig. 1) [16]. Although a
comparison between non-irradiated and irradiated clones may
demonstrate the effect of irradiation more clearly, the chances
of harvesting radio-resistant clones from non-irradiated cells
without selection would be very low. Thus we evaluated
stemness only on clones isolated by the method described
above.
CD133 was originally found as a marker on neural stem-
like cells [27–28]. In addition, CD133-positive cells were
reported to have strong tumor-initiating and multilineage
capacities in glioblastoma and medulloblastoma cells
[12–13, 29]. Therefore, CD133 is recognized as one of the
reliable markers of CSCs in these tumors. In this study, 20
selected radio-resistant clones expressed CD133 with a
range from 0.06 to 44%, and three clones showed predom-
inantly higher levels of CD133 positivity as compared with
parental ONS-76 (Table 1 and Fig. 1). In addition, we con-
firmed that these three clones were stable in maintaining
CD133 positivity even after 10 passages. Since it has been
reported that CD133-negative cells do not spontaneously
become CD133-positive after cell division, and irradiation
itself does not induce CD133 expression in CD133-negative
tumor cells, these three clones were most likely derived from
cells that were originally CD133-positive [8]. Thus, our ob-
servation may indicate that these CD133-positive clones
have strong self-renewal capacity to produce CD133-positive
cells in a symmetric cell division pattern. As for the other 17
clones with CD133-positive ratios ranging from 0.06–7.21%,
some of them may possess radio-resistant features due to
other mechanisms that are not directly related to stemness,
however, further characterization of these clones is out of the
scope of the present study.
Other characteristics of CSCs in glioblastoma and medul-
loblastoma cells are sphere formation ability in optimum
media [12, 30], and higher Hoechst 33342 effluxes side-
population [19, 31–34]. We demonstrated that the three
clones with high CD133-positive ratios also had signifi-
cantly higher D10 and SF2 values, sphere formation ability
and side-population fractions as compared with the parental
ONS-76 (Figs 2, 3, 4, Supplemental Fig. 3 and Table 2).
These results agree well with the reported data, which have
demonstrated that side-population cells were expressing
high levels of self-renewal-related genes such as notch and
PTEN in brain tumor cells [14, 35]. However, although we
performed double staining of CD133 and side-population
in FACS analysis, we could not find a close correlation
between these in the three isolated radio-resistant clones, in-
dicating that they may contain different subtypes of cells
with regard to stemness.
We observed that CD133-positive cells did not prolifer-
ate during the first 48 h of the incubation period, and they
grew very rapidly thereafter (Fig. 5B). This may demon-
strate that CD133-positive cells proliferated by symmetric
cell divisions after remaining in the resting (G0) state for a
latent period. Furthermore, maximum growth rates of
CD133-positive cells in the three isolated clones were sig-
nificantly higher than those to the parental ONS-76. From
these observations, these three isolated clones possess not
only self-renewal potency but also potentially high prolif-
erative ability in vitro (Fig. 5C).
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As for the mechanism of radio-resistance of CSCs, Bao
et al. reported that the expression levels of checkpoint-related
proteins such as ATM, Rad17, Chk1 and Chk2 were highly
up-regulated in CSCs after irradiation, resulting in accumula-
tion of cells in the cell cycle arrest in order to repair
damaged DNA [8]. In addition, Diehn et al. demonstrated
that CSCs had lower reactive oxygen species (ROS) levels
with less DNA damages, which may suggest that CSCs had
high radiation-induced free radical scavenge ability and
had lower incidence of radical-induced DNA damages [36].
Also, it has been reported that the self-renewal-related
notch pathway was closely associated with increase of the
CD133-positive cell fractions and increase of radio-resistance
in brain tumor cells [37]. Another self-renewal-related gene,
BMI-1, was also reported to enhance radio-resistance in brain
tumor cells [38]. These molecular analyses of the mechanism
of self-renewal and radio-resistance may add further informa-
tion to the characterization of the three clones isolated in this
study.
To improve tumor control we must initially clarify resist-
ance mechanisms. Elucidating the role of medulloblastoma
stem cells in tumor response to radiation will enhance our
understanding of the current status of radiotherapy against
this pediatric brain tumor, and may help direct our research
to achieving a more favorable outcome. Thus, future studies
should be aimed at defining a specific method to disrupt the
resistance mechanism of CSCs and improve overall tumor
control. As mentioned above, the checkpoint kinases or self-
renewal related genes may be possible molecular targets. At
this point, however, it is mandatory to proceed with studies,
not only to clarify the clinical applicability of these mole-
cules, but also to find other novel molecules that are respon-
sible for both stemness and radio-resistance.
In conclusion, we recreated the phenomenon of medullo-
blastoma recurrence after radiotherapy in vitro, and demon-
strated that at least three clones among 20 survivors with
high proliferative proficiency after γ-irradiation possess
cancer stemness. These results should contribute to eluci-
dating the mechanism of recurrence after radiotherapy in
patients with medulloblastoma.
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